FTDI
MYGN icon

First Trust Direct Indexing’s Myriad Genetics MYGN Stock Holding History

First Trust Direct Indexing’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,910
Closed -$58K – 764
2020
Q4 		$58K Buy
+2,910
New +$47K 0.02% 715

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

First Trust Direct Indexing's MYGN Position: Q1 2021 in Review

First Trust Direct Indexing sold out of Myriad Genetics (MYGN) in Q1 2021, closing a stake of 2,910 shares — an estimated $58K sold.

First Trust Direct Indexing first reported a position in MYGN in Q4 2020 and held it in 1 quarter. The position peaked at $58K in Q4 2020. 197 funds tracked by Wall St. Rank hold MYGN as of Q1 2021.

  • First Trust Direct Indexing reported no remaining Myriad Genetics position as of Q1 2021 after selling out during the quarter.
  • First Trust Direct Indexing sold 2,910 Myriad Genetics shares in Q1 2021, an estimated $58K.
  • First Trust Direct Indexing first reported a position in Myriad Genetics in Q4 2020 and held it in 1 quarter.
  • First Trust Direct Indexing's Myriad Genetics position peaked at $58K in Q4 2020.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2021.

Based on First Trust Direct Indexing's 13F filing for Q1 2021, filed 14 Apr 2021.